Zoetis Inc. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- Zoetis Inc. return tang equity for the quarter ending 2026-06-30 was -800.00%, a 576.42% decline year-over-year.
- Zoetis Inc. return tang equity for the quarter ending 2026-03-31 was -914.14%, a 567.90% decline year-over-year.
- Zoetis Inc. return tang equity for the quarter ending 2025-12-31 was -1894.29%, a 1015.90% decline year-over-year.
- Zoetis Inc. return tang equity for the quarter ending 2025-09-30 was 145.30%, a 9.23% decline year-over-year.
- Zoetis Inc. return tang equity for fiscal 2025 was -1215.00%, a 651.30% decline from fiscal 2024.
- Zoetis Inc. return tang equity for fiscal 2024 was 220.39%, a 6.25% increase from fiscal 2023.
- Zoetis Inc. return tang equity for fiscal 2023 was 207.43%, a 55.65% decline from fiscal 2022.
- Zoetis Inc. return tang equity for fiscal 2022 was 467.70%, a 31.79% increase from fiscal 2021.
- Available history
- 2011-12-31 to 2026-06-30
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |